AICAR Side Effects: What Human Trials Reported (2026)

The Documented Adverse Events, One at a Time

Hyperuricemia (Raised Uric Acid)

This is the most predictable AICAR effect because it is baked into the chemistry: AICAR is metabolized to uric acid. Acadesine cardiac-surgery trials documented asymptomatic uric-acid elevations of roughly 1.6 mg/dL, which were controlled with allopurinol in the trial protocols.

What trial data described as typical:

Asymptomatic elevation — detected on bloodwork, not felt as a symptom

Reversible; tied to active dosing rather than a lasting change

Managed in-trial with allopurinol when it occurred

Documented as most relevant to: individuals prone to gout or with a history of elevated uric acid, since a predictable urate load stacks on top of an existing tendency. Published reports frame the elevation as a metabolic consequence of the compound, not an allergic or idiosyncratic reaction.

Transient Renal Impairment (Raised Creatinine)

Acadesine trials in the perioperative setting documented transient renal impairment, seen as temporary rises in serum creatinine. In the trial context these were described as reversible. Because the data come from patients undergoing cardiac surgery — where kidney stress has multiple contributors — the trials cannot isolate how much is attributable to the compound alone in an otherwise healthy person.

Temporary creatinine elevation on bloodwork during dosing

Reversible in the reported trial timeframe

Documented alongside the uric-acid changes, consistent with a shared urate/renal-handling mechanism

Infusion-Related Hypotension

The acadesine trials documented infusion-related hypotension — drops in blood pressure associated with the intravenous infusion itself. This adverse event is route-specific: it is a property of pushing the drug intravenously over time in a surgical setting. Its relevance to a subcutaneous research-chemical protocol is undefined, because that route was never tested in a controlled human trial.

Injection-Site and Sterility Risks (Research-Chemical Products)

Separate from anything the acadesine trials measured, AICAR sold as a "research chemical, not for human consumption" carries the generic risks of any unregulated injectable: injection-site reactions, and contamination or sterility problems from products made outside pharmaceutical manufacturing controls. These are product-quality risks, not pharmacology of the molecule — they scale with the source, not the dose. Community sources commonly describe injection-site complaints, and note that AICAR's short half-life drives frequent dosing, which multiplies injection exposure.

The Red-Flag Categories: Where the Data Runs Out

Unlike a well-studied peptide, AICAR's most important safety issues are not a list of acute symptoms to watch — they are the places where human evidence simply does not exist. Three of them dominate.

The Long-Term Safety Blank

There is no dataset on repeated or chronic AICAR dosing in healthy people. Every human record is acute intravenous use during heart surgery. That means the long-term safety of the injected fitness-style protocols community sources describe is unknown — not "reassuringly studied and found safe," but genuinely undocumented. Reports of weeks-long self-administration come only from unregulated settings and were never tracked in a controlled trial.

The AMPK–Cancer Question (Unresolved, Two-Sided)

AICAR works by activating AMPK, and AMPK's relationship with cancer is one of the genuinely unsettled questions in the literature — and it cuts both ways. Most published AICAR cancer research describes anti-proliferative effects, with AMPK activation suppressing mTOR signaling and lipogenesis that tumors rely on. But AMPK activation can also be context-dependently pro-survival for an already-established tumor, helping it endure metabolic stress. Researchers treat this as an open question, not a proven danger and not a proven benefit. The reporting-accurate position is that no one can currently say which way it resolves in a human self-administering AICAR — which is itself a reason the compound sits outside settled safety ground.

Sport-Testing Consequences

AICAR is prohibited by the World Anti-Doping Agency at all times — both in and out of competition — under class S4 (hormone and metabolic modulators), in the AMPK-activator subsection. USADA names AICAR explicitly. This is not a health side effect, but for any tested athlete it is a certain and career-relevant consequence of use, and it applies year-round, not only on competition day.

How Community Sources Describe Limiting Exposure

Because there is no validated human protocol, there is also no trial-backed way to make AICAR "safer." The most that can be said is descriptive.

Community-reported risk-reduction patterns:

Community sources describe bloodwork monitoring of uric acid and creatinine, mirroring the two markers the acadesine trials flagged

Self-reported avoidance among individuals with gout history or existing kidney concerns, given the documented urate and renal signals

Community discussion of product-sterility and third-party testing as the dominant variable, since injection risk tracks source quality

The dosing guide covers why no validated human dose exists — the single most load-bearing safety fact about this compound

None of these is a trial-validated safeguard. They are community-reported patterns documented in unregulated settings, and they do not convert an investigational, never-approved compound into a characterized one.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.